Jefferies Reiterates Buy on Endo Pharmaceuticals (ENDP) on Restructuring News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Endo Pharmaceuticals (ENDP) New CEO Is the Real Deal - Jefferies
June 7, 2013 11:02 AM EDTJefferies reiterated a Buy rating and boosted its price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from $37 to $45 after CEO Rajiv DeSilva made his 1st public appearance at Jefferies conference Thursday.
Corey Davis comments, "Despite... More
Leerink Swann Upgrades Endo Pharma (ENDP) to Outperform
June 6, 2013 7:54 AM EDTLeerink Swann upgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Market Perform to Outperform with a modified price target of $48 (from $37). Analyst Michael Schmidt said he thinks guidance is now achievable since expectations have come down.
"We believe ENDP's new 2013 adjusted EPS... More
Cantor Fitzgerald Cuts Endo Pharma (ENDP) to Sell; Not Optimistic Restructuring
June 6, 2013 7:14 AM EDTCantor Fitzgerald downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Hold to Sell with a price target of $30.00 (from $36.00). Analyst Irina Rivkind is not optimistic about the company's restructuring plans.
"We don't think that a series of small deals, cost-cutting, and improved... More
Endo Health (ENDP) Acnnounces Cost Reductions; Will Trim Workforce 15%
June 5, 2013 4:17 PM EDTEndo Health Solutions (Nasdaq: ENDP) today outlined the strategic, operational and organizational steps it is taking to refocus the Company and drive shareholder value. These actions are the result of a comprehensive assessment of Endo's strengths and challenges, its cost structure and execution capabilities, and its most promising opportunities to drive future cash flow and earnings growth. Specifically, the Company announced plans to:
* Reduce annual operating expenses by $325 million
* Explore strategic alternatives for its HealthTronics business and branded pharmaceutical discovery platform
* Improve R&D efficiency and effectiveness, with a focus on development... More
